Open Endpoints

All endpoints currently open for prediction across 13 programs.

31
Open endpoints
55
Active predictions
13
Programs
OncologyASCO 2026IvonescimabSummit Therapeutics / Akeso
2 endpointsView program →

Hazard Ratio for Overall Survival (OS)

PRIMARYHazard Ratio
NCT05899608Range: 0.4 – 1.2 Hazard Ratio
4 predictions

Hazard Ratio for Progression-Free Survival (PFS)

PRIMARYHazard Ratio
NCT05899608Range: 0.3 – 1.1 Hazard Ratio
4 predictions
OncologyASCO 2026RetevmoEli Lilly
3 endpointsView program →

Hazard Ratio for Event-Free Survival (EFS)

PRIMARYHazard Ratio
NCT04819100Range: 0.3 – 1.1 Hazard Ratio
Predict →

Hazard Ratio for Progression-Free Survival (PFS)

Hazard Ratio
NCT04819100Range: 0.3 – 1.1 Hazard Ratio
Predict →

Hazard Ratio for Overall Survival (OS)

Hazard Ratio
NCT04819100Range: 0.4 – 1.2 Hazard Ratio
Predict →
OncologyVIR-5500Vir Biotechnology, Inc. / Astellas
1 endpointView program →

Objective Response Rate (ORR %)

PRIMARYResponse Rate
NCT05997615Range: 0 – 100 %
Predict →
OncologyASCO 2026Erleada (apalutamide)Johnson & Johnson
3 endpointsView program →

Pathological Complete Response Rate (pCR %)

PRIMARYResponse Rate
NCT03767244Range: 0 – 100 %
Predict →

Hazard Ratio for Overall Survival (OS)

PRIMARYHazard Ratio
NCT03767244Range: 0.4 – 1.2 Hazard Ratio
Predict →

Hazard Ratio for Event-Free Survival (EFS)

Hazard Ratio
NCT03767244Range: 0.3 – 1.1 Hazard Ratio
Predict →
OncologyASCO 2026Monjuvi (tafasitamab)Incyte / MorphoSys
2 endpointsView program →

Hazard Ratio for Event-Free Survival (EFS)

PRIMARYHazard Ratio
NCT04824092Range: 0.4 – 0.9 Hazard Ratio
Predict →

Hazard Ratio for Overall Survival (OS)

Hazard Ratio
NCT04824092Range: 0.4 – 1.2 Hazard Ratio
Predict →
ImmunologyZigakibart (BION-1301)Novartis
2 endpointsView program →

Primary Endpoint: Change from baseline in eGFR

PRIMARYBinary
NCT05852938"Will this trial meet its primary endpoint?"
Predict →

Primary Endpoint: Annualized rate of change in eGFR

Binary
NCT05852938"Will this trial meet its primary endpoint?"
Predict →
OncologySetidegrasibAstellas Pharma Global Development, Inc.
1 endpointView program →

Hazard Ratio for Overall Survival (OS)

PRIMARYHazard Ratio
NCT07409272Range: 0.4 – 1.2 Hazard Ratio
Predict →
OncologyBNT327 (pumitamig)BioNTech SE
4 endpointsView program →

Hazard Ratio for Overall Survival (OS)

PRIMARYHazard Ratio
NCT06712355Range: 0.4 – 1.2 Hazard Ratio
3 predictions

Hazard Ratio for Progression-Free Survival (PFS)

Hazard Ratio
NCT06712355Range: 0.3 – 1.1 Hazard Ratio
3 predictions

Objective Response Rate (ORR %)

Response Rate
NCT06712355Range: 0 – 100 %
3 predictions

Median Duration of Response (mDOR, months)

Median Survival
NCT06712355Range: 1 – 36 months
3 predictions
OncologyASCO 2026MezigdomideBristol-Myers Squibb
2 endpointsView program →

Hazard Ratio for Progression-Free Survival (PFS)

PRIMARYHazard Ratio
NCT05552976Range: 0.3 – 1.1 Hazard Ratio
3 predictions

Hazard Ratio for Overall Survival (OS)

Hazard Ratio
NCT05552976Range: 0.4 – 1.2 Hazard Ratio
3 predictions
OncologyASCO 2026DaraxonrasibRevolution Medicines, Inc.
3 endpointsView program →

Hazard Ratio for Progression-Free Survival (PFS)

PRIMARYHazard Ratio
NCT07491445Range: 0.3 – 1.1 Hazard Ratio
3 predictions

Hazard Ratio for Overall Survival (OS)

PRIMARYHazard Ratio
NCT07491445Range: 0.4 – 1.2 Hazard Ratio
3 predictions

Objective Response Rate (ORR %)

Response Rate
NCT07491445Range: 0 – 100 %
3 predictions
OncologyASCO 2026Datroway (datopotamab deruxtecan)AstraZeneca
4 endpointsView program →

HR for PFS in TROP2-positive nonsquamous patients

PRIMARYHazard Ratio
NCT05687266Range: 0.3 – 1.1 Hazard RatioReadout: Dec 2026
2 predictions

HR for OS in TROP2-positive nonsquamous patients

PRIMARYHazard Ratio
NCT05687266Range: 0.4 – 1.2 Hazard RatioReadout: Jan 2028
2 predictions

HR for PFS in nonsquamous ITT population

Hazard Ratio
NCT05687266Range: 0.3 – 1.2 Hazard RatioReadout: Dec 2027
2 predictions

HR for OS in nonsquamous ITT population

Hazard Ratio
NCT05687266Range: 0.3 – 1.2 Hazard Ratio
2 predictions
OncologyASCO 2026R-DXdDaiichi Sankyo
3 endpointsView program →

Objective Response Rate (ORR %)

PRIMARYResponse Rate
NCT06161025Range: 0 – 100 %
3 predictions

Hazard Ratio for Progression-Free Survival (PFS)

PRIMARYHazard Ratio
NCT06161025Range: 0.3 – 1.1 Hazard Ratio
3 predictions

Hazard Ratio for Overall Survival (OS)

Hazard Ratio
NCT06161025Range: 0.4 – 1.2 Hazard Ratio
3 predictions
OncologyASCO 2026ONO-4578Ono Pharmaceutical Co., Ltd.
1 endpointView program →

Hazard Ratio for Overall Survival (OS)

Hazard Ratio
NCT06256328Range: 0.4 – 1.2 Hazard Ratio
3 predictions